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Abstract
Oxidative stress produced by free radicals has been implicated in the pathogenesis of acute liver injury. The aim of our study was
to investigate whether melatonin, a potent antioxidant, could attenuate acute and chronic hepatic injury in rats. Acute liver injury
was induced by two consecutive intra peritoneal (i.p.) injections of thioacetamide (TAA; 300 mg/kg, i.p.) at 24 h intervals. Chronic
liver injury was induced by (TAA, i.p. injections for 6 weeks twice weekly, 50 mg/kg). Treatment with melatonin (3 mg/kg/daily,
i.p.) was initiated 24 h prior to and for 6 weeks post TAA intake. Rats in normal control group received intra-peritoneal injections
of normal saline at the same dose and frequency as those in treatment groups. At the end of experiment, animals were sacrificed,
liver was removed and weighed, and ratio to body weight was calculated. Serum activities of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), reduced glutathione (GSH) and malondialdehyde (MDA) concentration in liver homogenates
were assessed. We found that the acute and chronic experiments, liver weight, as well as liver weight/body weight ratio, ALT, AST,
GSH and MDA concentration were lower in rats treated with TAA + melatonin compared to acute and chronic TAA groups. Liver
histology was significantly improved and the mortality in the melatonin-treated rats was decreased indicating decreased oxidative
stress and inflammation. In conclusion both models results suggest that melatonin may be utilized to reduce liver injury associated
with oxidative stress.
© 2013 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.
 glutathKeywords: Liver injury; Malondialdehyde; Oxidative stress; Reduced
 Peer review under responsibility of Taibah University.
∗ Corresponding author at: Department of Physiology, Males Sec-
tion, College of Medicine, Taibah University, P.O. Box 30001,
Al-Madinah Al-Munawarah, Saudi Arabia. Tel.: +966 508761883;
fax: +966 048475790.
E-mail addresses: mfeb70@hotmail.com, mfeb70@gmail.com
(M.F. EL-Bab).
1658-3655 © 2013 Taibah University. Production and hosting by
Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.jtusci.2013.04.008ione; Melatonin
1.  Introduction
Oxidative stress has been accused in the genesis of
acute and chronic liver damage in many conditions such
as toxin exposures, bile duct obstruction, excess alcohol
intake, liver ischemia, and viral infection [1]. Overpro-
duction of reactive oxygen species (ROS) and nitrogen
species, together with a significant decrease of antioxi-
dant protection in these pathological conditions, disturbs
various cellular functions through the process of lipid
peroxidation [2]. Cirrhosis results from induction of
oxidative stress, mitochondrial dysfunction and deple-
tion of antioxidant status [3].
Common causes of acute liver failure include acute
viral hepatitis, and chemical- or toxin-induced liver
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njury [4], and can rapidly lead to failure of many organs
nd death while the liver transplantation is the only effec-
ive treatment [5].
Meanwhile, liver cirrhosis is a critical stage of chronic
iver diseases that can produce liver failure. It may be
ue to viral infection, toxic agents, or alcohol. The usual
reatment of liver cirrhosis is limited to the treatment
f the underlying cause [6]. Cirrhosis is defined as the
dvanced stage of fibrosis. Hepatic fibrosis can lead to
rreversible cirrhosis, and involves multiple cellular and
olecular events that ultimately result in hepatic accu-
ulation of collagen and extra cellular matrix protein,
his being directly responsible for the decrease of the
epatic function [7,8]. The accumulation of extracellu-
ar matrix observed in cirrhosis is due to the activation
f fibroblasts, that are produced by the activation of cell
recursors, such as hepatic stellate cells [9].
Many studies have been carried out to develop liver
ailure models. Surgical models include the use of
epatic ischemia and subtotal or total hepatectomy [10],
hile chemical models are produced by the use of drugs
nd toxins such as acetaminophen [11], carbon tetrachlo-
ide [12], galactosamine [13], and thioacetamide [14].
Thioacetamide [TAA] was originally used as a fungi-
ide [15]. TAA is a weak carcinogen that mainly affects
iver and kidney [16]. TAA has been considered to be an
nducer of liver fibrosis and cirrhosis [17]. The effects of
AA are not limited to the liver, but also many structural
nd functional disturbances have been described in the
idney [18], and spleen [19].
Liver cirrhosis induced by thioacetamide is associated
ith excessive lipid peroxidation [20] and the exhaus-
ion of antioxidant state [21]. In addition, thioacetamide
auses hepatocellular necrosis, and has been used to
xplore the role of reactive oxygen species [14].
In this regard, the decrease of the oxidative stress may
e useful to reduce cell injury, cirrhosis and fibrosis in
 variety of human diseases and experimental models of
iver damage [22,23]. Antioxidants can help to minimize
he oxidative stress, in cirrhotic livers [24]. Melatonin
N-acetyl-5-metyoxytryptamine) is a powerful endoge-
ous antioxidant, plays very important roles in regulation
f circadian rhythms, sleep, immune system activity, and
limination of oxygen free radicals [25,26], and exerts
ts antioxidant effects mainly through G protein depend-
nt receptors which lead to the induction of antioxidant
nzyme synthesis [27]. In this way, melatonin neutralizes
he effects of both oxygen- and nitrogen-based reactiveolecules [28].
Moreover, melatonin was demonstrated to interact
ith many toxic free radicals like peroxyl radicals, sin-
let oxygen species, and hydrogen peroxide [29,30].rsity for Science 7 (2013) 88–96 89
Melatonin may induce up regulation of the activ-
ity of antioxidants and antioxidant enzymes, such as
superoxide dismutase, glutathione peroxidase and glu-
tathione reductase [31]. Melatonin induces the activity of
-glutamylcysteinesynthetase, thereby stimulating the
production of another intracellular antioxidant, glu-
tathione [32].
Recent studies showed that melatonin exerts its cyto-
protective effects in various experimental models of
acute liver injury and reduces fibroblast proliferation
and collagen synthesis [33], indicating that melatonin
may have therapeutic effects on acute and chronic liver
injury, through its antioxidant action [34].
In the present study we evaluated the effect of
melatonin on oxidative stress damage in thioacetamide-
induced acute and chronic hepatic injury in rats.
2.  Materials  and  methods
2.1.  Animals
Male Albino rats, weighing between 150 and 250 g
at the beginning of the study. The animals were kept
in wire-floored cages under standard laboratory condi-
tions of 12 h light–dark cycle, 25 ±  2 ◦C with free access
to food and water. All animals were treated humanely
according to the international guidelines for the care of
animals.
2.2.  Chemicals
Thioacetamide was purchased from Sigma Chem-
ical Co., USA. Melatonin was purchased from
Sigma–Aldrich, St Louis, MO, USA.
Experimental induction of liver injury
- Acute liver damage was induced by two consecutive
injections of thioacetamide (300 mg/kg, i.p.) at 24 h
intervals [23].
- Chronic Liver damage was induced by thioacetamide
for 6 weeks (twice weekly 50 mg/kg, i.p. injections)
[35].
2.3.  Experimental  protocol
Ten animals were included in each of the following
five groups:- Group I [control group]: animals receiving daily i.p.
injections of saline.
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Rats in normal control group received daily i.p.
injections of saline at the same dose and frequency
as those in treatment groups.
- Group II (acute liver injury): acute liver injury was
induced by two consecutive injections of thioac-
etamide (300 mg/kg, i.p.) at 24 h intervals.
- Group III (melatonin and acute liver injury): animals
treated with melatonin (3 mg/kg/daily, i.p. diluted in
0.9% NaCl) was initiated 24 h prior to thioacetamide
and 6 weeks post its intake.
- Group IV [chronic liver injury]: chronic liver injury
was induced by thioacetamide for 6 weeks (twice
weekly 50 mg/kg, i.p. injections).
- Group V (melatonin and chronic liver injury): ani-
mals treated with melatonin were initiated 24 h prior
to thioacetamide at a dose of 3 mg/kg/daily, i.p. diluted
in 0.9% NaCl, and 6 weeks post thioacetamide intake.
After the last treatment, rats were fasted for 8 h and
subjected to sodium thiopental anesthesia (40 mg/kg.
i.p.) and sacrificed by cervical dislocation. The blood
samples were collected and centrifuged to obtain serum
in order to estimate total proteins, ALT, and AST.
The body weights of the animals in each group were
determined. The liver from each animal was weighed for
determination of the liver weight/body weight ratio. The
obtained rat liver homogenate was aliquoted and imme-
diately frozen at −20 ◦C for biochemical measurement
of reduced glutathione (GSH) content, and malondi-
aldehyde (MDA) concentration. Other liver pieces were
fixed in buffered 4% formalin and embedded in paraf-
fin. Sections of about 4 m thickness were stained with
hematoxylin and eosin (H&E) for the evaluation of his-
tological changes according to a described procedure
[36].
2.4.  Statistical  analysis
Data were analyzed statistically, using SPSS sta-
tistical package Version 13 and expressed as mean
(M) ±  standard deviation (SD). One-way analysis of
variance (ANOVA) was performed to compare different
groups and to determine overall effect of each treatment,
with a confidence level of 95% (p  < 0.05) considered
significant.
3.  Results3.1.  Body  weight
In TAA acute models (Groups II and III), the average
body weight showed no significant difference comparedersity for Science 7 (2013) 88–96
to the normal control group. Meanwhile there is a sig-
nificant increase in body weight of chronic models
(Groups IV and V) compared to the normal control group
(p < 0.001), and these significant changes may be consis-
tent with the age of the animals. The melatonin treated
chronic liver damage groups (Group V) showed a sig-
nificant increase in body weight compared to the acute
and chronic TAA-intoxicated animals (Groups II and IV)
(p < 0.001; Table 1).
3.2.  Liver  weight
The average liver weights of acute and chronic
TAA-intoxicated animals (Groups II and IV) showed sig-
nificant increase compared to the normal control group
(p < 0.001), The melatonin treated acute and chronic liver
damage groups (Groups III and V) showed a significant
increase in liver weights compared to the acute TAA-
intoxicated animals (Groups II; p  < 0.001 and Table 1).
3.3.  Liver  weight/body  weight  ratio
The mean relative liver weights of acute and chronic
TAA-intoxicated animals (Groups II and IV) showed
significant increase compared to the control group
(p < 0.001). Value of the mean relative liver weights
(LW/BW ratio) showed a significant increase in mela-
tonin treated acute liver damage group (Group III)
compared to the control group (p  < 0.01). Value of the
mean relative liver weights (LW/BW ratio) showed a
significant increase in melatonin treated chronic liver
damage group (Group V) compared to the control
group (p  < 0.05). The chronic TAA-intoxicated animals
(Groups IV) and the melatonin treated acute and chronic
liver damage groups (Group III and V) showed a sig-
nificant increase in LW/BW ratio compared to the acute
TAA-intoxicated animals (Group II) (p  < 0.001), and the
melatonin treated chronic liver damage groups (Group
V) showed a significant increase in liver weights com-
pared to the chronic TAA-intoxicated animals (Group
IV; p  < 0.001) (Table 1).
3.4.  Serum  liver  markers
Short term and long-term taken of TAA led to sig-
nificant increase of biochemical markers ALT, and AST,
(p < 0.001, Table 2) were compared to the control group,
indicating hepatocytes damage. Treatment of animals
with melatonin significantly reduced the level of liver
function biomarker (ALT, AST). The toxic effect of TAA
was controlled in the rats treated with melatonin and
that is approved by restoration of the levels of the liver
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Table 1
Body weight (BW) (g), liver weight (LW) (g) and liver weight (g)/body weight (g) ratio (LW/BW) ratio in different groups (mean ± SD).
Group No. BW LW LW/BW ratio
Group I 10 170.2 + 11.02 4.96 + 0.514 2.91 + 0.138
Group II 10 173.3 + 11.20 7.31 + 0.667* 4.22 + 0.246*
Group III 10 167.5 + 12.07 5.36 + 0.539# 3.55 + 0.429*,#
Group IV 10 211.6 + 13.71* 7.70 + 0.742* 3.67 + 0.310*,#
Group V 10 200.6 + 9.26*,#,$ 6.52 + 0.676# 3.07 + 0.171#,$
Group I: (control group), Group II (acute liver damage), Group III (melatonin and acute liver damage), Group IV (chronic liver damage), Group V
(melatonin and chronic liver damage).
* p < 0.001 vs normal control group.
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(# p < 0.05 vs acute model group.
$ p < 0.01 vs chronic model group.
iomarker. In acute liver injury treated with melatonin,
he effect was only marginal but still there was a sig-
ificant increase in liver enzymes (p  < 0.001, Table 2)
s compared to control group, whereas in chronic liver
njury, melatonin prevented the TAA-induced liver dam-
ge effectively.
MDA concentration (nmol/mg liver tissue) and GSH
ontent (g/mg liver protein) in liver tissue of different
roups of rats (Table 2)
Lipoperoxidation is a marker of cell membrane dam-
ge, and the measure of malondialdehyde, which is a
roduct of this damage. Here we have assessed lipoper-
xidation in the liver. We found a significant increase of
his marker in both models of the liver injury as compared
o the control group (p  < 0.01, Table 2) and a decrease
n the animals receiving melatonin as compared to
hioacetamide-intoxicated animals. In acute liver injury
reated with melatonin, the effect was only marginal but
till there was a significant increase in this liver tissue
arker (p  < 0.01, Table 2) as compared to control group,
hereas in chronic liver injury, melatonin prevented
he TAA-induced liver damage effectively. These data
howed that there is oxidative damage to the membrane
f these cells, and that melatonin decreases such damage.
able 2
erum aspartate transaminase (AST, IU/L), alanine transferase (ALT, IU/L), 
iver protein) in liver tissue of different groups of rats in different groups of ra
roup No. AST ALT 
roup I 10 118.33 ± 13.53 58.42 
roup II 10 438.32 ± 61.21* 223.76 
roup III 10 241.65 ± 42.96*,# 112.11 
roup IV 10 283.18 ± 43.57* 101.66 
roup V 10 126.28 ± 13.68# 65.11 
roup I: (control group), Group II (acute liver damage), Group III (melatonin
melatonin and chronic liver damage).
* p < 0.001 vs normal control group.
# p < 0.05 vs acute model group.GSH could scavenge the lipid peroxide radicals,
lipid hydroperoxides and other products which is a
toxic metabolite of thioacetamide. Therefore, we mea-
sured the content of GSH in liver tissue of rats. From
Table 2, we can clearly see the vast difference between
thioacetamide-intoxicated group and the control group,
and the level of GSH was largely decreased (p  < 0.001,
Table 2). Our results showed that the recovery of the
GSH level was near to normal level in chronic models
treated with melatonin compared to acute models treated
with melatonin.
3.5.  Histological  examination
To confirm the protective effect of Melatonin on
TAA-induced liver tissue damage, we performed his-
tological examinations (Fig. 1). The normal control
rat liver sections showed normal regular cellular archi-
tecture of hepatic lobules with distinct hepatic cells,
sinusoidal spaces, and a central vein. The hepatic
cells displayed prominent nuclei and uniform cyto-
plasm (Fig. 1A). However, TAA-intoxicated rat liver
elicited decrease in the number of hepatocytes, mas-
sive hepatocytic necrosis, including bridging necrosis,
MDA concentration (nmol/mg liver tissue) and GSH content (g/mg
ts (mean ± SD).
MDA GSH
± 7.80 0.010 ± 0.003 0.058 ± 0.008
± 38.41* 0.032 ± 0.020* 0.029 ± 0.007*
± 11.64*,# 0.018 ± 0.002* 0.041 ± 0.006*
± 15.66* 0.021 ± 0.003* 0.034 ± 0.007*
± 8.78# 0.012 ± 0.003# 0.052 ± 0.007#
 and acute liver damage), Group IV (chronic liver damage), Group V
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l (A), a
 (F) staFig. 1. Microscopic view of liver section obtained from normal contro
treated with melatonin (E), chronic liver injury treated with Melatonin
with influx of inflammatory cells (Fig. 1B and C). The
liver sections of the chronic TAA-intoxication revealed
extensive damage, characterized by severe necrosis, fatty
degeneration, sinusoidal dilatation and congestion, cen-
trilobular necrosis, proliferation of bile duct, presence of
collagen bundles surrounding the lobules, which lead
to thick fibrotic septae that disrupts the cellular
architecture (Fig. 1D). On the other hand, TAA-
intoxicated rats administered with Melatonin revealed
significant marked regeneration of the hepatocytescute liver injury (B and C), chronic liver injury (D), acute liver injury
ined with hematoxylin and ×1200. Photomicrograph of liver section.
with preservation of the normal hepatic architecture,
reduced level of necrosis, narrow fibrotic septae, and
remarkable increase in bile ductules, fat storing cells,
and Kupffer cells (Fig. 1E). Excellent liver recov-
ery was indicated in rats administered with melatonin
in chronic model with liver morphology compara-
ble to the control rats. There was minimal disruption
of the hepatic cellular structure, very minor fibrotic
septae and a low degree of lymphocyte infiltration
(Fig. 1F).
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.  Discussion
Recently, there has been a growing understand-
ng of the pathophysiology behind fibrosis, which has
ontributed to the development of agents that could
otentially inhibit and even reverse the fibrotic process
n the future [37]. Among various hepatotoxins, TAA
s known to be the most potent because of its rapid
limination and cumulative injury. The present study
howed that TAA administration for 6 weeks induced
iver fibrosis with many histopathological alterations.
hese observations were in agreement with many pre-
ious studies, which investigated the induction of liver
brosis and cirrhosis by TAA in experimental animals
38] and [39].
In the present study, although there were no sig-
ificant changes in body weights in the different
xperimental groups except for Groups IV and V
chronic models) and this is consistent with the age,
igher liver weights as well as liver body weight ratios
ad been observed in TAA-treated rats compared to rats
n control groups. Measurement of liver body weight
atio is a more accurate approach to determine the
hanges in liver size compared to the measurement of
iver weight alone as the liver weight largely depends on
he size of the rat. The enlargement of livers in TAA-
reated rats signified hepatic lesions and liver injury
ssociated with the toxic effects of thioacetamide. These
ignificant changes in the liver weights may be attributed
o the accumulation of collagen and extra cellular matrix
rotein in liver tissue [8]. However, the liver enlargement
as significantly reduced (p  < 0.05) in rats treated with
elatonin.
Serum liver biomarkers (ALT, AST) are important
riteria for the evaluation of liver toxicity. The amounts
f enzymes that leak into the blood stream indicate the
everity of hepatic damage [40] and [41]. In the present
tudy, the rats intoxicated with thioacetamide experi-
nced hepatic injury evidenced by significant increase
p < 0.05) in serum liver biomarkers (AST and ALT)
hen compared to normal control rats. However, mela-
onin exhibited hepatoprotective effects to attenuate the
levated serum liver parameters, but the effectiveness of
elatonin in the attenuation of the elevated liver enzymes
as observed more in treated chronic model than treated
cute model.
The increased serum levels of AST and ALT are due to
he damage to the structural integrity of the liver, since
hese enzymes are normally located in the cytoplasm
nd released into the circulation after cellular injury
42]. Also Hajovsky et al. [43] reported that thioac-
tamide produces free radicals, which affect the cellularrsity for Science 7 (2013) 88–96 93
permeability of hepatocytes leading to elevated levels of
serum biochemical parameters like ALT, and AST.
It was suggested that hepatotoxins including TAA
induced liver damage by forming free radicals, which
then react with cellular lipids to promote lipid
peroxidation [44]. The higher MDA level in TAA con-
trol rats observed in the present study also supports this
suggestion.
Generally, malondialdehyde (MDA) is used as an
index of lipid peroxidation, and lipid peroxidation is pos-
tulated as the mechanism of free radical induced tissue
injury, hence free radical scavenging is established as the
means by which antioxidants inhibit lipid peroxidation.
Malondialdehyde has been quantified since the 1960s
and is still widely used as a biomarker to detect lipid
peroxidation due to the low cost and simplicity of the
application [45].
Our results showed that melatonin in both acute
and chronic models (3 mg/kg) significantly reduced the
hepatic MDA content (Table 1). This result is consistent
with previous reports that indicated melatonin showed
free radical scavenging properties and protective effects
on hepatotoxicity induced in rats by thioacetamide [46]
and by irradiations [47]. However, the hepatoprotective
activity of melatonin in chronic liver injury seemed to
be better than to that of melatonin in acute injury. These
data show that there is oxidative damage to the mem-
brane of these cells, and that melatonin decreases such
damage [48].
Reduced glutathione is an important endogenous
antioxidant system that is found in particularly high
concentration in liver, and it is known to have key
functions in protective processes. The reduced form of
GSH becomes readily oxidized to glutathione disul-
fide (GSSG) on interacting with free radicals. Excessive
production of free radicals resulted in the oxidative
stress, which leads to damage of macromolecules, e.g.
lipids and can induce lipid peroxidation in  vivo  [49]. In
our study, TAA depleted tissue GSH significantly. The
post-treatment of animals with melatonin significantly
decreased the TAA-induced changes of this oxidative
stress marker.
The reductions of endogenous antioxidant enzymes
in cirrhotic animals, together with the results of lipoper-
oxidation, establish a picture of oxidative stress in these
animals [50]. Melatonin treatment reduced lipoperoxida-
tion and increased level of reduced glutathione, showing
a significant improvement of the oxidative stress in these
animals [51–53].
The data lead us to suggest that melatonin decreases
the oxidative stress by acting as scavenger of free radicals
and providing antioxidant protection of biomolecules.
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Melatonin significantly reduces the lipoperoxidation lev-
els in liver, and increases the antioxidant substances in
the liver tissue.
We suggest that the major reason is that, while the
production of the free radicals with various chemical
properties in these diseases is widely spread throughout
the different tissue and cellular components, the chemi-
cal property of an individual antioxidant can only allow
it to scavenge the free radicals located in a specific cel-
lular component, e.g., lipid or aqueous phase. Moreover,
the efficacy of an antioxidant substance is also dependent
on the redox state of the cell. In situations that an imbal-
anced redox state preexisted, antioxidant treatment will
be less, or none, effective [54]. It has been suggested
recently that the therapeutic strategy for protecting
against oxidative stress will be to target simultaneously
the free radicals in both the lipid and the aqueous phases,
in extracellular and intracellular spaces [55].
Histologically, in our study, TAA administration
produced severe periportal inflammation with pigment
deposition and also scattered inflammatory cell infiltra-
tion in the hepatic lobule. The post-treatment of animals
with melatonin, reversed significantly TAA-intoxicated
pathogenic changes in liver. A mild periportal inflam-
mation with no pigmentation or necrosis was observed
in the liver sections of animals treated with TAA and
melatonin.
As previously mentioned, acute TAA toxicity leads
to the prominent changes in the liver tissue architecture
including the appearance of necrotic cells and inflam-
matory cells, mostly macrophages around the central
vein. TAA produces centrilobular necrosis with marked
accumulation of lipids on acute exposure [56].
5.  Conclusion
Based on our results, the concentration of daily
3 mg/kg melatonin is likely to provide significant pro-
tection against acute and chronic liver injuries induced
by thioacetamide and is a potentially beneficial agent to
reduce liver damage by decreasing oxidative stress. Fur-
ther experiments and clinical trials remain necessary to
validate these findings.
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